Treatment outcomes and deaths among multidrug-resistant tuberculosis (MDR-TB) patients in Gomel region, Belarus – 2009-2010 Source: Annual Congress 2013 –Drug-resistant tuberculosis: new clinical and public health insights Year: 2013
Active pharmacovigilance for multidrug-resistant tuberculosis patients treated with Linezolid, Belarus – 2014-2015 Source: International Congress 2015 – Treatment of TB (MDR-TB): co-morbidities, adverse effects and outcomes Year: 2015
Active drug-safety monitoring and management for tuberculosis patients treated with bedaquiline and linezolid, Belarus – 2014-2016 Source: International Congress 2016 – Update on drug-resistant tuberculosis Year: 2016
Trend and risk factors of drug resistance tuberculosis between 2005-2012 in Istanbul, Turkey Source: International Congress 2015 – Management of TB: a patient focus Year: 2015
The top of the iceberg - Extensively drug resistant tuberculosis (XDR-TB) in 2010 Source: International Congress 2015 – Epidemiology of TB: deaths, co-morbidities, migration and children Year: 2015
Transmission pattern of MDR-TB in Singapore 2005-2015 Source: International Congress 2016 – Rifampicin resistance, MDRTB, and new drug treatments Year: 2016
Fifteen years period (2000-2014) of resistant TB forms in Vojvodina (Serbia) Source: International Congress 2015 – Management of TB: a patient focus Year: 2015
Estimating costs for treating patients with multi-drug resistant tuberculosis (MDR TB) under the regional tuberculosis control program, Tomsk (Russia) Source: International Congress 2015 – Treatment of TB (MDR-TB): co-morbidities, adverse effects and outcomes Year: 2015
MDR TB treatment results of GFATM program implementation in Tomsk, Russia Source: International Congress 2015 – Management of TB: a patient focus Year: 2015
Features of different M.tuberculosis strains that were isolated from MDR-TB patients in Kharkiv, Ukraine Source: International Congress 2016 – Epidemiological insights into tuberculosis pathogenesis Year: 2016
Rifampicin-resistant tuberculosis (RR-TB) in eastern Europe Source: International Congress 2016 – Rifampicin resistance, MDRTB, and new drug treatments Year: 2016
Prevalence of fluoroquinolon-resistance among different MDR tuberculosis cases in Ukraine Source: Annual Congress 2013 –Drug-resistant tuberculosis Year: 2013
Trend in TB control in Republic of Moldova: High MDRTB burden country Source: International Congress 2014 – Tuberculosis: epidemiology and public health Year: 2014
Steps of bedaquline implementation in Georgia Source: International Congress 2016 – Drug-resistant tuberculosis and experiences with delamanid and bedaquiline Year: 2016
Treatment outcomes among multidrug-resistant tuberculosis (MDR-TB) cases at a referral hospital of infectious diseases in Italy Source: International Congress 2016 – Update on drug-resistant tuberculosis Year: 2016
Predisposing factors of multi drug resistant tuberculosis (MDR-TB) in Sardjito Hospital, Yogyakarta, Indonesia in 2009-2012 Source: International Congress 2014 – Tuberculosis: from epidemiology to therapy 1 Year: 2014
Prevalence and trend of ofloxacin-resistance among MDR-TB including XDR-TB cases in Ukraine Source: International Congress 2015 – Epidemiology of TB: deaths, co-morbidities, migration and children Year: 2015
Current status of fluoroquinolone use for treatment of tuberculosis in Korea Source: Annual Congress 2013 –Drug-resistant tuberculosis Year: 2013
Risk factor and resistance pattern of MDR TB among suspected cases of Oromia Region Source: International Congress 2015 – Epidemiology of TB: deaths, co-morbidities, migration and children Year: 2015
Multidrug–resistant tuberculosis in Czech Republic during the period of recent 5 years (2007-2012) Source: Annual Congress 2013 –Tuberculosis: epidemiology and public health management II Year: 2013